FDA
-
-
-
-
-
-
-
Zai Lab reports intracranial response data for lung cancer drug
-
-
-
-
-
-
-
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates
-
-
-
-
-
-
-
Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates
-
-
-
-
-
-
-
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
-
-
-
-
-
-
-
Zai Lab (ZLAB) Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
-
-
-
-
-
-
-
Morgan Stanley on Zai Lab (ZLAB) Post BMY (BMY) Approval: 'We believe it should bode moderately positively for ZLAB shares'
-
-
-
-
-
-
-
Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
-
323,580 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

